SEC Form 4 · accession 0001209191-19-007478
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John F Crowley
Officer — Chairman & CEO · Director
Period of report
Feb 1, 2019
Accepted (ET)
Feb 5, 2019 · 6:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 1, 2019 | M | 20,000 | $3.82 | A | 688,081 | D | |
| Common StockF2 | Feb 1, 2019 | S | 20,000 | $12.116 | D | 668,081 | D | |
| Common Stock | holding | — | — | — | 64,895 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F3 | $3.82 | Feb 1, 2019 | M | 20,000 | D | — | Jun 26, 2024 | Common Stock | 20,000 | 210,000 | D |
Explanation of responses
- F1The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018.
- F2This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.96 to $12.41. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3All of the options were fully vested and exercisable as of February 1, 2019.
Remarks
The options exercised in the transaction represent approximately 1.08% of Mr. Crowley's ownership at the time of the transaction. Mr. Crowley intends to exercise his options on a monthly basis.